Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial
Barbara D. Wamil, Gary B. Thurman, Hakan W. Sundell, Russel F. DeVore, Gail Wakefield, David H. Johnson, Yue-Fen Wang, Carl G. HellerqvistVolume:
123
Année:
1997
Langue:
english
Pages:
7
DOI:
10.1007/bf01214670
Fichier:
PDF, 703 KB
english, 1997